936 related articles for article (PubMed ID: 23615075)
21. [Evaluating efficacy of transcatheter arterial chemo-embolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT].
Zhao M; Wu PH; Zeng YX; Zhang FJ; Huang JH; Fan WJ; Gu YK; Zhang L; Tan ZB; Lin YE
Ai Zheng; 2005 Sep; 24(9):1118-23. PubMed ID: 16159437
[TBL] [Abstract][Full Text] [Related]
22. [Diagnostic accuracy of 18F-FDG positron emission tomography for evaluation of hepatocellular carcinoma].
Shin JA; Park JW; An M; Choi JI; Kim SH; Kim SK; Lee WJ; Park SJ; Hong EK; Kim CM
Korean J Hepatol; 2006 Dec; 12(4):546-52. PubMed ID: 17237633
[TBL] [Abstract][Full Text] [Related]
23. Tumor-to-muscle ratio of 8F-FDG PET for predicting histologic features and recurrence of HCC.
Baek YH; Lee SW; Jeong YJ; Jeong JS; Roh YH; Han SY
Hepatogastroenterology; 2015; 62(138):383-8. PubMed ID: 25916068
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis.
Lin CY; Chen JH; Liang JA; Lin CC; Jeng LB; Kao CH
Eur J Radiol; 2012 Sep; 81(9):2417-22. PubMed ID: 21899970
[TBL] [Abstract][Full Text] [Related]
25. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH
Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma.
Detry O; Govaerts L; Deroover A; Vandermeulen M; Meurisse N; Malenga S; Bletard N; Mbendi C; Lamproye A; Honoré P; Meunier P; Delwaide J; Hustinx R
World J Gastroenterol; 2015 Mar; 21(10):3049-54. PubMed ID: 25780305
[TBL] [Abstract][Full Text] [Related]
27. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective.
Cheung TT; Ho CL; Lo CM; Chen S; Chan SC; Chok KS; Fung JY; Yan Chan AC; Sharr W; Yau T; Poon RT; Fan ST
J Nucl Med; 2013 Feb; 54(2):192-200. PubMed ID: 23321459
[TBL] [Abstract][Full Text] [Related]
28. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma.
Asman Y; Evenson AR; Even-Sapir E; Shibolet O
Liver Transpl; 2015 May; 21(5):572-80. PubMed ID: 25644857
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation.
Gao Y; Zheng DY; Cui Z; Ma Y; Liu YZ; Zhang W
World J Gastroenterol; 2015 Sep; 21(36):10418-26. PubMed ID: 26420968
[TBL] [Abstract][Full Text] [Related]
30. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE.
Song HJ; Cheng JY; Hu SL; Zhang GY; Fu Y; Zhang YJ
Clin Radiol; 2015 Feb; 70(2):128-37. PubMed ID: 25459673
[TBL] [Abstract][Full Text] [Related]
31. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
[TBL] [Abstract][Full Text] [Related]
32. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
33. F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI.
Santra A; Kumar R; Sharma P; Bal C; Kumar A; Julka PK; Malhotra A
Eur J Radiol; 2012 Mar; 81(3):508-13. PubMed ID: 21353420
[TBL] [Abstract][Full Text] [Related]
34. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
35. [Application of contrast-enhanced ultrasonography in selecting indication of radiofrequency ablation among hepatocellular carcinoma patients].
Chen MH; Wu W; Yang W; Gao W; Dai Y; Yin SS; Huo L; Yan K
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3491-4. PubMed ID: 16686066
[TBL] [Abstract][Full Text] [Related]
36. F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma.
Wu HB; Wang QS; Li BY; Li HS; Zhou WL; Wang QY
Clin Nucl Med; 2011 Dec; 36(12):1092-7. PubMed ID: 22064078
[TBL] [Abstract][Full Text] [Related]
37. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases.
Donckier V; Van Laethem JL; Goldman S; Van Gansbeke D; Feron P; Ickx B; Wikler D; Gelin M
J Surg Oncol; 2003 Dec; 84(4):215-23. PubMed ID: 14756432
[TBL] [Abstract][Full Text] [Related]
38. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma.
Lee JW; Paeng JC; Kang KW; Kwon HW; Suh KS; Chung JK; Lee MC; Lee DS
J Nucl Med; 2009 May; 50(5):682-7. PubMed ID: 19372474
[TBL] [Abstract][Full Text] [Related]
39. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
40. Determination of vitality of liver lesions by alveolar echinococcosis. Comparison of parametric contrast enhanced ultrasound (SonoVue®) with quantified 18F-FDG-PET-CT.
Kaltenbach TE; Graeter T; Mason RA; Kratzer W; Oeztuerk S; Haenle MM; Gruener B; Gottstein M
Nuklearmedizin; 2015; 54(1):43-9. PubMed ID: 25423884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
